The second day of ASCO has been filled with a wealth of exciting research. Take a look at some of our highlights below and make sure to let us know your thoughts in the comments below or on social media.
Remember you can find us at booth #4040, or follow our Twitter updates @OncologyCentral.
MSI-H tumor patients more likely to have Lynch Syndrome, genomic study demonstrates
A genomic study of more than 15,000 tumor samples, led by researchers at Memorial Sloan Kettering Cancer Center (NY, USA), demonstrates that patients with tumors that have high microsatellite instability (MSI-H) are more likely to have Lynch syndrome. Among individuals with MSI-H tumors, 16% were subsequently found to have Lynch syndrome. Additionally researchers managed to link several new cancers to the syndrome.
Early-stage lung cancer: could blood tests be used as a potential detection tool?
Researchers have revealed a report from the large, ongoing Circulating Cell-Free Genome Atlas (CCGA) study that a blood test may be able to detect early-stage lung cancer in patients. This is one of the first studies to utilize blood tests that analyze free-floating or cell-free DNA as a potential tool for the early detection of cancer.
Taselisib, combined with Faslodex®, halts growth of advanced breast cancer
Results from a Phase lll clinical trial, assessing the effectiveness of a new targeted drug, taselisib, have demonstrated promising results against advanced breast cancer when combined with standard hormone therapy fulvestrant (Faslodex®).
It wasn’t long ago that the only distinction doctors could make in lung cancer was whether it is small cell or non-small cell lung cancer. We’ve come so far, yet have so far to go- let’s keep the momentum going! #LCSM#ASC018pic.twitter.com/Hp7gZoc06B